Nonviral vectors containing polypropyleneimines
JP2026048823A5Pending Publication Date: 2026-07-13UNIV GENT
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- JP2025247590
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-12-17
- Filing Date
- 2025-12-12
- Publication Date
- 2026-07-13
AI Technical Summary
Technical Problem
Current non-viral vectors for nucleic acid delivery suffer from low transfection efficiency and cytotoxicity, hindering their clinical application.
Method used
A pharmaceutical composition comprising polypropyleneimine (PPI) polymers with a degree of polymerization of 20 to 1000, preferably 100 to 500, and polyethyleneimine (PEI) polymers, forming copolymers with a high PPI content, which are used to complex nucleic acids, achieving high transfection efficiency and low cytotoxicity.
Benefits of technology
The composition exhibits high transfection efficiency and low cytotoxicity, making it suitable for in vivo use with small particle size and improved stability.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000000_0000_ABST
Abstract
This invention provides for the field of nonviral vectors and pharmaceutical compositions, as well as their use in human or veterinary medicine. [Solution] The present invention relates to a pharmaceutical composition comprising a polymer or copolymer of polypropyleneimine for the delivery or transfection of nucleic acids, such as RNA. The pharmaceutical compositions described herein are particularly useful for (nucleic acid) vaccination, nucleic acid-based protein therapy, nucleic acid-based protein replacement therapy, gene editing, base editing, cell therapy, immunotherapy, stem cell therapy, regenerative medicine, gene silencing, nucleic acid inhibition, or protein inhibition. In a first embodiment, a novel composition comprising a polypropyleneimine polymer (PPI) and a nucleic acid is provided. More specifically, the present invention provides a pharmaceutical composition comprising a PPI and a nucleic acid, wherein the PPI has a degree of polymerization of about 20 to 1000, preferably about 100 to 500, and most preferably about 200 to 300.
Need to check novelty before this filing date? Find Prior Art